Mark G. Edwards
Founder chez BioScience Advisors, Inc.
Profil
Mark G.
Edwards was the founder of Recombinant Capital, Inc. (founded in 1988) and BioScience Advisors, Inc. (founded in 2011) where he held the title of Managing Director.
He currently holds the position of Director at The Scripps Research Institute, California Institute for Biomedical Research, and Prolynx LLC.
Mr. Edwards received his undergraduate degree and MBA from Stanford University.
Postes actifs de Mark G. Edwards
| Sociétés | Poste | Début |
|---|---|---|
BioScience Advisors, Inc.
 BioScience Advisors, Inc. Investment ManagersFinance BioScience Advisors, Inc. engages in consulting and database firm focused on biopharma alliances. It specializes in biotechnology alliances, ip valuation, expert witness, pharmaceutical licenses, market trends, financial terms and contract provisions. The company was founded by Mark G. Edwardsin January 2011 and is headquartered in Walnut Creek, CA. | Founder | 01/01/2011 |
California Institute for Biomedical Research
 California Institute for Biomedical Research Miscellaneous Commercial ServicesCommercial Services The California Institute for Biomedical Research provides biomedical research services. The non-profit company is based in La Jolla, CA. | Director/Board Member | - |
The Scripps Research Institute
 The Scripps Research Institute Other Consumer ServicesConsumer Services The Scripps Research Institute is a private, non-profit research organizations that performs basic biomedical research in molecular & cellular biology, chemistry, immunology and neuroscience. They receive the majority of its funding from federal agencies such as the National Institutes of Health. The organization also partners with pharmaceutical companies and is affiliated with the Scripps hospital group. The organization was founded in 1955 and is headquartered in La Jolla, California. | Director/Board Member | 01/02/2017 |
Prolynx LLC
 Prolynx LLC Miscellaneous Commercial ServicesCommercial Services Prolynx LLC engages in the development of proprietary drug delivery system for half-life extension of proteins, peptides, and small molecules. Its pipeline includes PLX038, PEG-PARP, IL-15, IL-2, PTH 1-34, GLP-1RA, and QMo IVT. The company was founded by Daniel V. Santi and Gary W. Ashley in 2010 and is headquartered in San Francisco, CA. | Director/Board Member | 01/12/2019 |
Anciens postes connus de Mark G. Edwards
| Sociétés | Poste | Fin |
|---|---|---|
| TALPHERA, INC. | Director/Board Member | 31/03/2022 |
| Deloitte Recap LLC | Corporate Officer/Principal | 01/12/2010 |
Recombinant Capital, Inc.
 Recombinant Capital, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Deloitte LLP (New York), Recombinant Capital, Inc. is a private company that provides life sciences subscription database and advisory services. The company is based in Walnut Creek, CA. The company was founded by Mark G. Edwards. Recombinant Capital was acquired by Deloitte Touche Tohmatsu Services LLC on June 16, 2008. | Founder | 01/01/2008 |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Director/Board Member | 19/06/2007 |
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Corporate Officer/Principal | - |
Formation de Mark G. Edwards
| Stanford University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| TALPHERA, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Health Technology |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
Recombinant Capital, Inc.
Recombinant Capital, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Deloitte LLP (New York), Recombinant Capital, Inc. is a private company that provides life sciences subscription database and advisory services. The company is based in Walnut Creek, CA. The company was founded by Mark G. Edwards. Recombinant Capital was acquired by Deloitte Touche Tohmatsu Services LLC on June 16, 2008. | Commercial Services |
BioScience Advisors, Inc.
BioScience Advisors, Inc. Investment ManagersFinance BioScience Advisors, Inc. engages in consulting and database firm focused on biopharma alliances. It specializes in biotechnology alliances, ip valuation, expert witness, pharmaceutical licenses, market trends, financial terms and contract provisions. The company was founded by Mark G. Edwardsin January 2011 and is headquartered in Walnut Creek, CA. | Finance |
| Deloitte Recap LLC | |
Prolynx LLC
Prolynx LLC Miscellaneous Commercial ServicesCommercial Services Prolynx LLC engages in the development of proprietary drug delivery system for half-life extension of proteins, peptides, and small molecules. Its pipeline includes PLX038, PEG-PARP, IL-15, IL-2, PTH 1-34, GLP-1RA, and QMo IVT. The company was founded by Daniel V. Santi and Gary W. Ashley in 2010 and is headquartered in San Francisco, CA. | Commercial Services |
California Institute for Biomedical Research
California Institute for Biomedical Research Miscellaneous Commercial ServicesCommercial Services The California Institute for Biomedical Research provides biomedical research services. The non-profit company is based in La Jolla, CA. | Commercial Services |
